Pull to refresh
Logo
Daily Brief
Following Why Sign Up
Tinnitus device Lenire added to U.S. ENT guidelines, first new treatment since 2014

Tinnitus device Lenire added to U.S. ENT guidelines, first new treatment since 2014

Rule Changes

American Academy of Otolaryngology includes bimodal neuromodulation in updated clinical practice guidelines

Today: Neuromod announces Lenire's guideline inclusion

Overview

Updated 1 hour ago

The American Academy of Otolaryngology added Lenire, a device that pairs sound with mild tongue stimulation, to its clinical practice guidelines for tinnitus. It's the first new treatment added since the guidelines were created in 2014.

The update gives more than 12,000 U.S. ear, nose, and throat specialists a guideline-backed option for the roughly 50 million Americans who report tinnitus. The guidelines also recommend against repetitive transcranial magnetic stimulation, a treatment some clinics had offered.

Why it matters

For the 50 million Americans with tinnitus, ENTs now have a guideline-backed, FDA-approved treatment to offer instead of managing symptoms alone.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

50M+
Americans reporting tinnitus
More than 50 million people in the U.S. have reported experiencing tinnitus.
12,000+
U.S. ENTs covered by guidelines
Practicing ear, nose, and throat specialists who can now recommend Lenire.
81.8%
Real-world response rate
Patients with moderate or worse tinnitus who achieved clinically significant improvement in a U.S. cohort study.
2023
Year FDA approved Lenire
The Food and Drug Administration granted De Novo approval in March 2023.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

DO
Dr. Ross O'Neill
Founder, Neuromod Devices
Active
PL
Professor Hubert Lim
Chief Scientific Officer, Neuromod Devices
Active

Organizations Involved

AA
American Academy of Otolaryngology – Head and Neck Surgery Foundation
Medical Professional Association
Publisher of the updated tinnitus guidelines

The professional association for U.S. ear, nose, and throat specialists, which publishes clinical practice guidelines for tinnitus.
Neuromod Devices
Neuromod Devices
Medical Device Company
Manufacturer of Lenire

Dublin-based company that developed Lenire, the first FDA-approved bimodal neuromodulation device for tinnitus.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal Regulatory Agency
Approved Lenire via De Novo pathway in 2023

The federal agency that granted De Novo approval to Lenire, making it the first and only FDA-approved bimodal neuromodulation device for tinnitus.

Timeline

2014 October 2026

5 events Latest: Today
Tap a bar to jump to that date

  1. Neuromod announces Lenire's guideline inclusion

    Today Announcement

    Neuromod Devices announces Lenire is the first new treatment added to the AAO-HNSF tinnitus guidelines since 2014.

  2. AAO-HNSF publishes updated tinnitus guidelines

    Guideline

    The updated clinical practice guideline includes bimodal neuromodulation as a treatment option and recommends against repetitive transcranial magnetic stimulation.

  3. Real-world evidence study published

    Research

    A U.S. cohort study finds 81.8% of patients with moderate or worse tinnitus achieve clinically significant improvement with Lenire.

  4. FDA grants De Novo approval to Lenire

    Regulatory

    The Food and Drug Administration approves Lenire as the first bimodal neuromodulation device for tinnitus.

  5. AAO-HNSF publishes first tinnitus guidelines

    Guideline

    The American Academy of Otolaryngology establishes its first clinical practice guidelines for tinnitus.

Scenarios

1

Lenire becomes standard of care for U.S. tinnitus patients

Likely Resolves by End of 2028

Discussed by: Neuromod Devices, AAO-HNSF

With guideline inclusion, more ENTs prescribe Lenire. Insurance coverage expands as the guideline gives payers a basis for reimbursement. The device becomes a first-line treatment for bothersome tinnitus, similar to how hearing aids became standard after guideline endorsement.

2

Adoption lags as ENTs stick with established treatments

Possible Resolves by End of 2028

Discussed by: Medical device adoption analysts

Despite guideline inclusion, adoption is slow. ENTs continue to recommend hearing aids and cognitive behavioral therapy, which have longer track records. Lenire remains a niche option at specialized tinnitus centers rather than a mainstream treatment.

3

Rival bimodal devices enter the market

Possible Resolves by End of 2028

Discussed by: Medical device industry observers

The guideline inclusion validates the bimodal neuromodulation category. Competitors develop similar sound-plus-stimulation devices and seek FDA approval. The market expands beyond Lenire, potentially driving prices down and increasing patient access.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

March 2023

FDA De Novo approval of Lenire (2023)

The FDA granted De Novo approval to Lenire, creating a new regulatory category for bimodal neuromodulation devices. The approval was based on the TENT-A3 controlled clinical trial, whose results were published in Nature Communications and ranked in the 99th percentile of most-viewed articles tracked by the journal.

Then

Lenire became the first FDA-approved bimodal neuromodulation device for tinnitus.

Now

The approval established the regulatory pathway for future devices in this category.

Why this matters now

The 2023 FDA approval was the regulatory foundation that made the 2026 guideline inclusion possible.

2014

AAO-HNSF 2014 tinnitus guidelines

The American Academy of Otolaryngology published its first clinical practice guidelines for tinnitus, establishing a framework for diagnosis and treatment. The guidelines recommended hearing aids, sound therapy, and cognitive behavioral therapy.

Then

ENTs gained a standardized approach to tinnitus care.

Now

The 2014 guidelines became the baseline that the 2026 update revises.

Why this matters now

The 2026 update is the first revision of these guidelines, and Lenire is the only new treatment added.

2023

TENT-A3 pivotal trial (2023)

Neuromod's pivotal TENT-A3 controlled clinical trial provided the evidence base for FDA approval. The results were published in Nature Communications, a top-tier scientific journal.

Then

The trial data supported FDA's De Novo approval of Lenire.

Now

The published results became the evidence cited in the 2026 clinical guidelines.

Why this matters now

The trial's publication in a peer-reviewed journal gave the AAO-HNSF panel the evidence needed to include bimodal neuromodulation in its guidelines.

Sources

(6)
+2
PR Newswire American Academy of Otolaryngology – Head and Neck Surgery Physician in the Loop American Journal of Audiology PR Newswire American Academy of Otolaryngology – Head and Neck Surgery